Drug-Induced Cognitive Impairment and Dementia

被引:0
|
作者
O. D. Ostroumova [1 ]
T. M. Ostroumova [2 ]
A. I. Kochetkov [1 ]
A. E. Vorobyova [1 ]
A. A. Gadzhibekov [3 ]
D. A. Sychev [1 ]
机构
[1] Russian Medical Academy of Continuing Professional Education,
[2] Russian Ministry of Health,undefined
[3] Sechenov First Moscow State Medical University (Sechenov University),undefined
[4] Russian Ministry of Health,undefined
[5] Central Clinical Hospital “RZD-Medicine”,undefined
关键词
cognitive impairment; dementia; drug-induced diseases; drug-induced cognitive impairment/dementia; adverse drug reactions;
D O I
10.1007/s11055-024-01686-8
中图分类号
学科分类号
摘要
Causes of the development or aggravation of cognitive impairment (CI) may include the use of a number of drugs, including non-steroidal anti-inflammatory drugs, antiarrhythmics, antidepressants, glucocorticosteroids, antitumor drugs, and various others. The adverse effects of drugs on cognitive functions are mediated by many pathophysiological mechanisms: disruption of hormonal regulation, decreased neuronal excitability, increased γ-aminobutyric acid receptor activity, decreased cerebral blood flow, and atrophic changes in the brain; many mechanisms remain to be established definitively. Risk factors for the development of drug-induced (DI) CI are old age, childhood, brain damage, chronic diseases, and genetic factors, along with the presence of early CI in the patient, polypharmacy, dose and duration of drug use, acute infectious diseases, metabolic disorders, dehydration, acute urinary retention, and others. The diagnosis and differential diagnosis of DI CI requires a connection between the start of taking the proposed drug inductor and CI to be established. The first step in the treatment of DI CI is discontinuation of the inducing drug or reduction in the dosage; when discontinuation of the drug is not possible and there is no replacement, special slow-release dosage forms can be considered. The main measures to prevent DI CI include the use of drugs with the lowest risk of their development, assessment of drug interactions, and the use of modern scales to assess the risk of developing this side effect (such as the anticholinergic burden scale).
引用
收藏
页码:870 / 877
页数:7
相关论文
共 50 条
  • [41] Mild Cognitive Impairment and Dementia
    Clapp, Melissa
    PSYCHOLOGIST, 2013, 26 (12) : 907 - 907
  • [42] Vascular cognitive impairment and dementia
    Gorelick, Philip B.
    Counts, Scott E.
    Nyenhuis, David
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2016, 1862 (05): : 860 - 868
  • [43] DRUG-INDUCED DISEASES - DRUG-INDUCED METABOLIC DISEASE
    RICHARDS, P
    BRITISH MEDICAL JOURNAL, 1979, 1 (6171): : 1128 - 1129
  • [44] Dementia and cognitive impairment in Argentina
    Arizaga, RL
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 78 - 79
  • [45] Mild cognitive impairment and dementia
    Albert, Marilyn S.
    Blacker, Deborah
    ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, 2006, 2 : 379 - 388
  • [46] Vascular Cognitive Impairment and Dementia
    Iadecola, Costantino
    Duering, Marco
    Hachinski, Vladimir
    Joutel, Anne
    Pendlebury, Sarah T.
    Schneider, Julie A.
    Dichgans, Martin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (25) : 3326 - 3344
  • [47] Depression with dementia and cognitive impairment
    Lyketsos, CG
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 379 - 379
  • [48] DRUG-INDUCED DISEASES - DRUG-INDUCED HEMATOLOGICAL DISEASE
    DAWSON, AA
    BRITISH MEDICAL JOURNAL, 1979, 1 (6172): : 1195 - 1197
  • [49] Drug-Induced Hepatotoxicity or Drug-Induced Liver Injury
    Pugh, Aaron J.
    Barve, Ashutosh J.
    Falkner, Keith
    Patel, Mihir
    McClain, Craig J.
    CLINICS IN LIVER DISEASE, 2009, 13 (02) : 277 - +
  • [50] DRUG-INDUCED TRANQUILIZATION VS DRUG-INDUCED AGITATION
    MUSZYNSKI, H
    MAFFETT, ER
    AMERICAN JOURNAL OF PSYCHIATRY, 1959, 115 (11): : 1029 - 1030